Summary of Key Points Core Viewpoint - The company has decided to postpone the expected operational readiness date for part of its fundraising investment projects, specifically the "Chongqing Ruide Sida Optoelectronic Materials Project," from August 2025 to February 2026, based on prudent principles and current project progress [1][4]. Group 1: Fundraising Overview - The company issued 47,894,302 A-shares, raising a total of approximately 580 million RMB, with a net amount of about 568 million RMB after deducting issuance costs [1]. - The funds raised are intended for specific investment projects, including the acquisition of a 75% stake in Qingdao Hongdie New Materials Co., Ltd., and the pure manganese sulfate project [2]. Group 2: Project Delay Details - The delay in the "Chongqing Ruide Sida Optoelectronic Materials Project" is due to the need for additional time for equipment installation and debugging, as well as the completion of some ancillary works [3][4]. - The project has completed its main construction, but certain payments related to the project are pending due to contractual agreements [4]. Group 3: Impact and Compliance - The postponement of the project does not alter the project’s implementation entity, the intended use of the raised funds, or the investment scale, ensuring compliance with relevant regulations [4][5]. - The company has taken measures to ensure that the project will be completed on schedule despite the delay, including close monitoring of market changes and resource allocation [4].

Core Viewpoint - The company has decided to extend the investment timeline for certain fundraising projects, specifically the "Drug Clinical Research Project," to align with actual progress and strategic goals, without altering the project's content or financial commitments [3][6][8]. Fundraising Overview - The company raised a total of RMB 1,334,792,400.00 through the issuance of 30,090,000 shares at RMB 44.36 per share, with a net amount of RMB 1,222,708,416.51 after deducting issuance costs [1][2]. - The funds are stored in a dedicated account, and a regulatory agreement is in place with the sponsor and the bank [1]. Investment Project Details - The company has made adjustments to its fundraising project allocations, including a change in the use of RMB 61 million from the "Marketing Network Construction Project" to fund a new project for its subsidiary [2]. - The total investment for the new project is RMB 10,905 million, with RMB 6,100 million sourced from the adjusted funds [2]. Project Timeline Adjustments - The investment period for the "Drug Clinical Research Project" has been extended by two years, now set to conclude on August 31, 2027 [6][8]. - The project includes two sub-projects: the "Vildagliptin Tablets" and "Morphine Sulfate and Naloxone Controlled-Release Capsules," with the former having completed Phase III trials [6]. Reasons for Delay - The delay is attributed to the need for additional clinical trials for the "Vildagliptin Tablets" to meet submission requirements for market approval, considering competitive market conditions and commercialization risks [6][8]. Impact of Delay - The project delay is deemed a prudent decision that will not adversely affect the company's normal operations or alter the investment's total amount, purpose, or scale [8][9]. Approval Process - The board and supervisory committee have approved the project delays, confirming that no shareholder meeting is required for this decision [8][9]. - Both the board and supervisory committee emphasize that the delay is in the best interest of shareholders and aligns with the company's long-term sustainable development [9]. Sponsor's Review - The sponsor has reviewed the project delay and found that all necessary approval procedures have been followed, with no changes to the project's financial commitments or objectives [9].

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced a two-year extension for the investment period of its "Drug Clinical Research Project" due to the actual progress of the project and to align with the company's long-term development strategy [1][4]. Fundraising Overview - The company raised a total of RMB 1,334,792,400.00 through the issuance of 30,090,000 shares at a price of RMB 44.36 per share, with a net amount of RMB 1,222,708,416.51 after deducting issuance costs [1][2]. - The funds are stored in a dedicated account, and a regulatory agreement has been signed with the sponsoring institution and the bank [1]. Investment Project Details - The company has adjusted the investment allocation for its fundraising projects, including a change in the use of RMB 61 million from the "Marketing Network Construction Project" to fund a new project for its subsidiary, Shod Pharmaceutical [2][3]. - The total investment for the "Drug Clinical Research Project" is RMB 11,400.00 million, with RMB 7,384.91 million already spent, indicating a progress rate of 64.78% [3]. Project Delay Specifics - The investment deadline for the "Drug Clinical Research Project" has been extended from September 2, 2025, to August 31, 2027, to accommodate additional clinical trials required for the project [3][4]. - The delay is attributed to the need for further clinical trials for the drug "Uroglitazone" to meet submission requirements for market approval [3][4]. Impact of Delay - The extension of the investment period is a prudent decision based on the project's actual implementation status and will not adversely affect the company's normal operations or the project's overall objectives [4][5]. - The board and supervisory committee have both approved the delay, confirming that it does not involve changes to the project's total investment, purpose, or scale [4][5].

证券代码：001222 证券简称：源飞宠物 公告编号：2025-037 温州源飞宠物玩具制品股份有限公司 温州源飞宠物玩具制品股份有限公司（以下简称"公司"）于2025年8月11日 召开第三届董事会第六次会议，审议通过了《关于部分募集资金投资项目延期的 议案》，同意公司将募投项目"研发中心建设项目"达到预期可使用状态日期由 施方式、募集资金投资用途，不会对募投项目的实施造成实质性影响。保荐机构 光大证券股份有限公司对本事项出具了明确的核查意见。该事项无需提交公司股 东会审议。现将具体情况公告如下： 一、募集资金投资项目情况 公司对募集资金的存放和使用采取了专户存储管理，并与保荐机构、存放募 集资金的商业银行签署了募集资金三方监管协议。 截至2025年7月31日，公司募集资金投资项目的具体情况如下： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《关于核准温州源飞宠物玩具制品股份有限公 司首次公开发行股票的批复》（证监许可[2022]1280号），并经深圳证券交易所 同意，公司于2022年8月向社会公开发行人民币普通股3,410万股， ...

Group 1 - The company, Wenzhou Yuanfei Pet Toy Co., Ltd., has announced a delay in the implementation of certain fundraising investment projects due to various factors affecting the execution timeline [1][5] - The total amount raised from the public offering was approximately 467.51 million RMB, with 34.1 million shares issued at a price of 13.71 RMB per share [1][4] - The company has established a dedicated account for the management of raised funds and signed a tripartite supervision agreement with the sponsor and the commercial bank [2][4] Group 2 - The company has adjusted the timeline for the "R&D Center Construction Project" to December 31, 2026, due to delays in construction and approval processes [5][6] - The delay is deemed necessary to enhance the efficiency of fund usage and to align with the company's long-term strategic goals [5][6] - The board of directors has approved the delay, confirming that it does not harm the interests of the company or its shareholders [6]

Group 1 - The company announced a cash dividend distribution of 0.15 yuan per share for the fiscal year 2024, approved at the annual shareholders' meeting on June 25, 2025 [2][4] - The total cash dividend distribution amounts to approximately 141.13 million yuan, based on a total share capital of 940,996,515 shares, excluding shares held in the repurchase account [4][6] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the record date [3][4] Group 2 - The company plans to postpone the completion dates for two fundraising investment projects: the "Jixi Branch Phase III Construction Project" to August 2026 and the "Traditional Chinese Medicine Material Processing Project" to October 2026 [11][22] - The postponement is due to external environmental factors affecting project progress, and the company aims to enhance the quality of the investment projects [22][25] - The board of directors approved the postponement during the meeting held on August 11, 2025, and the decision will be submitted for approval at the upcoming shareholders' meeting [26][36] Group 3 - The company intends to provide a guarantee for its wholly-owned subsidiary, Heilongjiang Zhenbaodao Medical Trade Co., Ltd., for bank financing up to 400 million yuan [29][30] - The guarantee is deemed necessary to support the subsidiary's operational needs, with the board considering the risk to be manageable [35][36] - The total amount of external guarantees provided by the company is 1.791 billion yuan, which accounts for 22.96% of the latest audited net assets [37]

Core Viewpoint - The company has announced a delay in the expected operational status of two fundraising investment projects, extending the timeline for the "Jixi Branch Phase III Project" to August 2026 and the "Traditional Chinese Medicine Material Processing Project" to October 2026 [1][4][10] Fundraising Overview - The company raised a total of RMB 1,237,999,917.28 through a non-public offering of 92,803,592 shares at a price of RMB 13.34 per share, with a net amount of RMB 1,217,240,132.22 after deducting issuance costs [1][2] - The funds are stored in a dedicated account, and a three-party/four-party supervision agreement has been signed [1] Investment Project Details - The company has made adjustments to its fundraising investment projects due to changes in market conditions and policy adjustments, including the termination of certain sub-projects and reallocating funds to other projects [2][3] - The "Jixi Branch Phase III Project" involves the construction of a chemical synthesis workshop and related facilities, with construction progress affected by industry policies and competition [8] Delay Reasons and Measures - The delays in project timelines are attributed to construction progress lagging behind the original schedule, necessitating a cautious review and adjustment of the expected operational status [6][9] - The company plans to implement measures to ensure compliance and efficient use of the raised funds, including strict supervision of project progress [9] Approval Process - The delay in the investment projects was approved by the company's board of directors, following necessary procedures and compliance with relevant regulations [10]

Group 1 - The company Zhejiang Huaye Plastic Machinery Co., Ltd. has postponed the investment projects funded by its initial public offering (IPO) due to various factors including the late arrival of funds and changes in project locations [1][4]. - The total amount raised from the IPO was RMB 417.4 million, with a net amount of RMB 356.32 million after deducting issuance costs [1][2]. - The company has signed a regulatory agreement with the commercial bank managing the raised funds to ensure proper oversight [2]. Group 2 - The adjusted investment plan includes a total investment of RMB 672 million, with the net amount from the IPO allocated to specific projects [3]. - The postponement of the investment projects does not involve changes to the project content, implementation methods, or investment amounts, ensuring that shareholder interests are maintained [4][5]. - The board of directors and the supervisory board have approved the postponement, confirming that all necessary procedures have been followed [5].

兴业证券股份有限公司 关于福建海峡环保集团股份有限公司 部分募集资金投资项目延期的核查意见 兴业证券股份有限公司（以下简称"兴业证券"或"保荐机构"）作为福建 海峡环保集团股份有限公司（以下简称"海峡环保"）2022 年非公开发行股票 的保荐机构，根据《证券发行上市保荐业务管理办法》、《上市公司监管指引第 市规则》及《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法 律法规及规范性文件的规定，对海峡环保 2022 年非公开发行股票部分募集资金 投资项目（以下简称"募投项目"）延期事项进行了核查，核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准福建海 峡环保集团股份有限公司非公开发行股票的批复》（证监许可〔2022〕501 号） 核准，海峡环保非公开发行股票 84,158,415 股，每股发行价格人民币 6.06 元。 募集资金总额为人民币 50,999.99949 万元，扣除发行费用（不含增值税）人民币 的 XYZH/2022XMAA10155 号《非公开发行股票募集资金验资报告》验证。海 峡环保开立了募集资金专户，募集资金已全部存放于经董事会批 ...

Group 1 - The core point of the announcement is the approval of the extension of a fundraising investment project without changing the total investment amount or the purpose of the funds [1][2] - The project in question is the construction of a special polymer material production facility with an annual capacity of 45,000 tons [1] - The decision was made during the seventh meeting of the fifth supervisory board, which was held on August 1, 2025, with all three supervisors present [1][2] Group 2 - The vote on the extension proposal resulted in 3 votes in favor, with no votes against or abstentions [2] - The company assures that the extension does not negatively impact the implementation of the fundraising project or the interests of shareholders [1] - The announcement also complies with relevant regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange regarding the management of raised funds [1]